Waystar Considers Sale Amid Stock Slump, Sources Reveal
Waystar is exploring strategic options, including a sale, following a 24% drop in its stock value this year.
Waystar, a prominent healthcare software provider, is reportedly considering a range of strategic options, including a possible sale, just two years after going public. This development comes as the company faces a significant decline in its market valuation. According to sources familiar with the situation, Waystar has engaged investment bank Evercore to assist in exploring these possibilities.
Potential Return to Private Ownership
The Lehi, Utah, and Louisville, Kentucky-based firm is evaluating whether to return to private ownership, a move that could be influenced by its current market performance. Despite its initial public offering (IPO) success in 2024, Waystar's stock has faced challenges, plummeting 24% this year amid a broader downturn in the software sector. This decline has left the company's market value at approximately $4.8 billion.
Waystar's strategy has been to position itself as a technology company, focusing on automating and managing administrative tasks in healthcare, rather than as a traditional healthcare services provider. This approach aimed to attract higher valuations typical of tech companies. However, concerns about the impact of artificial intelligence on software businesses have pressured its stock, according to a report by Morgan Stanley analysts in July.
Background and Ownership
Founded in 2017 through the merger of Zirmed and Navicure, Waystar has become a key player in healthcare revenue management. The company went public with backing from major investors, including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. Currently, EQT is the largest shareholder, holding a 13% stake, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with 8%, based on data from LSEG.
While the exploration of a sale is at an early stage, sources caution that plans could change, and a sale might not occur. Neither Waystar nor its major investors have commented on the potential sale, and Evercore has not responded to requests for comment.
Implications for the Software Sector
The potential sale of Waystar could serve as a barometer for investor interest in the software industry, particularly within the healthcare segment. As the company evaluates its future, the outcome could influence perceptions of the viability and attractiveness of similar software enterprises in a volatile market environment.
Waystar's exploration of strategic options highlights the ongoing challenges and opportunities within the healthcare technology sector, as companies navigate market fluctuations and technological advancements.